Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Toxicity Spectrum of Anti-GD2 Immunotherapy: A Real-World Study Leveraging the US Food and Drug Administration Adverse Event Reporting System

Published:2023-12-28 Issue: Volume: Page:
ISSN:1174-5878
Container-title:Pediatric Drugs
language:en
Short-container-title:Pediatr Drugs

Author:

Wang Guangfei^ORCID,Wang Jinglin,Du Ruxiang,Wang Yi,Li Zhiping

Funder

Shanghai Medicine and Health Development Foundation

Shanghai Young Pharmaceutical Talent Ability Improvement Program

Excellent Young Clinical Pharmacist Training Program in Children's Hospital of Fudan University

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Pediatrics, Perinatology and Child Health

Link

https://link.springer.com/content/pdf/10.1007/s40272-023-00613-7.pdf

Reference38 articles.

1. Jin QY, Du SB, Yuan XJ. Exploring the prognosis of neuroblastoma in adolescents and adults: a case series and literature review. Neoplasma. 2022;69(2):464–73.

2. Spasov N, Spasova M. Early use of dinutuximab beta in patients with high-risk neuroblastoma. Case Rep Pediatr. 2021;2021:6610955.

3. Cabral J, Fernandez EI, Toy B, Secola R. Multidisciplinary clinical care in the management of patients receiving anti-GD2 immunotherapy for high-risk neuroblastoma. Paediatr Drugs. 2023;25(1):13–25.

4. Mastrangelo S, Rivetti S, Triarico S, Romano A, Attinà G, Maurizi P, et al. Mechanisms, characteristics, and treatment of neuropathic pain and peripheral neuropathy associated with dinutuximab in neuroblastoma patients. Int J Mol Sci. 2021;22(23):12648.

5. Ahmed AA, Zhang L, Reddivalla N, Hetherington M. Neuroblastoma in children: update on clinicopathologic and genetic prognostic factors. Pediatr Hematol Oncol. 2017;34(3):165–85.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Multidimensional assessment of adverse events of finasteride: a real-world pharmacovigilance analysis based on FDA Adverse Event Reporting System (FAERS) from 2004 to April 2024;2024-08-22

2. Adverse event profile of memantine and donepezil combination therapy: a real-world pharmacovigilance analysis based on FDA adverse event reporting system (FAERS) data from 2004 to 2023;Frontiers in Pharmacology;2024-07-17

3. Anti-GD2 monoclonal antibody-associated ADRs;Reactions Weekly;2024-01-27

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3